Why I think GlaxoSmithKline and this company are two of the best shares to buy now

GlaxoSmithKline pairs well with this company and I reckon they are two of the best shares to buy now for quality, growth and income in my portfolio.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Exactly one year ago, I thought pharmaceutical giant GlaxoSmithKline (LSE: GSK) and Beximco Pharmaceuticals (LSE: BXP) were attractive stocks. Today, I still reckon they’re two of the best shares to buy now.

The pharmaceutical sector is a rich hunting ground for defensive, cash-producing and recession-resistant businesses. And I’m a big fan of steady dividend income and growth potential. Meanwhile, over the past year, these two stocks haven’t been standing still.

Why I think they are two of the best shares to buy now

With its share price near 1,475p, GlaxoSmithKline is just over 14% below the level of a year ago. There’s been some disruption to operations because of the pandemic. But the company continued trading, including making a big effort in pursuit of a workable vaccine for Covid-19.

Last spring, the directors declared their intention to maintain shareholder dividend payments at a flat level for the year. And I think that move demonstrates the resilience of the business under stress conditions – exactly what’s needed from my defensive investments.  However, despite steady trading, the shares declined and bottomed at the end of October.

To me, the value looks compelling now. For example, the forward-looking earnings multiple for 2021 is around 12.5. And the anticipated dividend yield is about 5.4%. But those attractive numbers are from a company delivering a return on capital of almost 15% and an operating margin just over 25%. To me, the figures suggest both quality and value, so I’d be happy to buy the stock today.

Meanwhile, at 70p, generic medicines producer Beximco Pharmaceuticals has a stock price changing hands around 65% higher than it was a year ago. And some of the move has arisen because of an upwards valuation re-rating. It appears investors are beginning to appreciate the attractions of the highly-regulated business that’s based in Bangladesh.

The growth story is on track at Beximco

But the valuation remains fair. The forward-looking earnings multiple for the trading year to June 2021 is around 10 and the anticipated dividend yield is a little over 3% — and earnings should cover the payment more than three times. Meanwhile, the business has been delivering an operating margin of just under 22% and a return on capital of 15%.

I think Beximco’s quality and value metrics look similar to GlaxoSmithKline’s. However, Beximco’s market capitalisation at £284m is tiny compared to GlaxoSmithKline’s almost £74bn. But I’m comfortable with that situation because Beximco could have more room to grow its operations.

And today’s full-year results report demonstrates the company’s recent progress introducing new medicines to the Bangladesh home market and abroad. Indeed, there’s been expansion in the US, Europe and the rest of the world. Meanwhile, despite the pandemic, revenue increased by just over 12% year on year, and earnings per share rose by almost 16%.

The directors held the cash dividend flat for the year but declared a stock dividend of 10 new shares for every 100 held by shareholders. I reckon the way the firm is sharing its success with investors speaks volumes about the directors’ confidence in the outlook. I’d be pleased to buy some of the shares today and hold for the long haul.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any share mentioned. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Will it be too late to buy Nvidia stock in March?

NVIDIA stock is up more than 60% since the start of 2024. Our writer considers whether it might still be…

Read more »

Typical street lined with terraced houses and parked cars
Investing Articles

Why did Direct Line shares just soar 27%?

Direct Line shares have jumped more than a quarter in the course of today's trading session. Our writer explains why…

Read more »

Close-up of British bank notes
Investing Articles

These 2 shares are Dividend Aristocrats. Which should I buy this March?

Our writer likes the business model of this pair of FTSE 100 Dividend Aristocrats. So why would he only consider…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Investing Articles

I bought 49 Unilever shares in June. Here’s what they’re worth today

Harvey Jones bought a modest amount of Unilever shares last summer hoping the stock would soon recover. He's having to…

Read more »

BUY AND HOLD spelled in letters on top of a pile of books. Alongside is a piggy bank in glasses. Buy and hold is a popular long term stock and shares strategy.
Investing Articles

I reckon these shares, potentially 20% undervalued, are Warren Buffett’s type of investment

Oliver Rodzianko thinks Games Workshop is an absolutely stellar investment. As it's potentially undervalued, he reckons Warren Buffett would agree.

Read more »

Calendar showing the date of 5th April on desk in a house
Investing Articles

Great investing habits that can boost my Stocks and Shares ISA

Forget complicated calculations and financial jargon! Our writer uses a few simple habits to build wealth inside his Stocks and…

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

Why has the St. James’s Place share price crashed 30%, after FY results?

The St. James's Place share price has just fallen off a cliff. What could have gone wrong in 2023 that's…

Read more »

Family in protective face masks in airport
Investing Articles

Here’s how much I’d have if I’d bought 1,000 Rolls-Royce shares 10 years ago

Rolls-Royce shares may be flying high this year but that wasn't always the case. I'm calculating how much I'd have…

Read more »